


Company Overview

Michael Egholm

September 28, 2022



Legal Information

Forward-Looking Statements

This presentation and the accompanying oral presentation contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the expected advantages of and demand for Standard BioTools products, new product introductions, anticipated placements of products, strategies and plans for market access and growth, and expectations for growth by business line. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks associated with the potential adverse effects of the coronavirus pandemic on our business and operating results; possible transition-related disruption, including through the loss of customers, suppliers and employees; changes in Standard BioTools' business or external market conditions; customers and prospective customers continuing to curtail or suspend activities utilizing our products; our ability and/or the ability of the research institutions utilizing our products and technology to obtain and maintain Emergency Use Authorization from the FDA or any other requisite authorizations or approvals to use our products and technology for diagnostic testing purposes; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, Standard BioTools products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; Standard BioTools research and development and distribution plans and capabilities; interruptions or delays in the supply of components or materials for, or manufacturing of, Standard BioTools products; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Standard BioTools' business and operating results is contained in its Annual Report on Form 10-K for the year ended December 31, 2021, and in its other filings with the Securities and Exchange Commission ("SEC Filings"). These forward-looking statements speak only as of the date hereof. Standard BioTools disclaims any obligation to update these forward-looking statements except as may be required by law.

Market, Industry and Other Data

This presentation includes estimates regarding market and industry data. Unless otherwise indicated, information concerning our industry and the markets in which we operate, including our general expectations, market position, market opportunity and market size, are based on our management's knowledge and experience in the markets in which we operate, together with currently available information obtained from various sources, including publicly available information, industry reports and publications, surveys, our customers, trade and business organizations, and other contacts in the markets in which we operate. Certain information is based on management estimates, which have been derived from third-party sources, as well as data from our internal research. In presenting this information, we have made certain assumptions that we believe to be reasonable based on such data and other similar sources and on our knowledge of, and our experience to date in, the markets in which we operate. Market and industry data, which is derived in part from management's estimates and beliefs, are subject to change and may be limited by the availability of raw data, the voluntary nature of the data-gathering process, and other limitations inherent in any statistical survey of such data. In addition, projections, assumptions and estimates of the future performance of the markets in which we operate, and our future performance are necessarily subject to uncertainty and risk due to a variety of factors, including those described in "Risk Factors" in the Standard BioTools' SEC Filings. These and other factors could cause results to differ materially from those expressed in the estimates made by third parties and by us.

Trademarks

Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, the CyTOF XT logo, "Unleashing tools to accelerate breakthroughs in human health," Biomark, Biomark X, CyTOF, CyTOF XT, Hyperion, Hyperion+, Imaging Mass Cytometry, IMC, Juno, and Maxpar are trademarks and/or registered trademarks of Standard BioTools Inc. (f.k.a. Fluidigm Corporation) or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. ©2022 Standard BioTools Inc. All rights reserved. 09/2022


Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.

Information in this is subject to change without notice. Patent and License Information: www.standardbiotools.com/legal/notices.



Standard BioTools™ Introduction

- Life sciences platform company focused on translational cutting-edge technologies
- Continued innovation of core technologies from Fluidigm®: Mass Cytometry and Microfluidics
- Application development and support to enable customers and become a preferred partner
- Broadened ambition: bring other solutions to market that add value to our customers workflows



Cutting-edge tools that enable scientists to make breakthroughs faster and more efficiently



Focus on standardized workflows that provide unsurpassed reliability, repeatability and consistency



Commitment to continuous improvement, quality and customer service

Portfolio of High-Parameter Multi-Omic Technologies

Flow cytometry



CyTOF[®] XT
Flow Cytometry



Maxpar[®] Assays
and Kits

- 50+ unique markers at one time
- Rapid panel design
- Easy swapping of markers
- Identify new cell populations
- Enables longitudinal and cross-center studies

Spatial Imaging




Hyperion+[™] Imaging
System

- 40+ unique markers at one time
- Artifact-free imaging of FFPE tissue
- Rapid panel design and swapping of markers
- 1 mm² region of interest ROI in 1 hour
- Clinical quality data

Microfluidics and PCR



Biomark X[™] PCR
Platform






IFC
96x96 | 48x48
192x24

- Up to 192 unique primer/probe sets
- Rapid panel design
- Easy swapping of probes
- Up to 100-fold reduction in reagent and sample consumption
- Readout of 9,216 reactions in < 1 hour




50+ "Color" Resolution

Superior data quality and ease of panel design compared to fluorescence-based detection

Fluorescence




Mass Cytometry



Advantages and Limitations of Different Approaches


Low-plex IHC



Common diagnostic technique with automated workflow

- Only few markers per tissue section
- High inter-observer variability
- Missed opportunities to gain important prognostic and diagnostic insights


Cyclical staining



More markers with each cycle

- Cycles take time but image large tissue areas (incl. TMAs)
- Workflow a challenge
- Low barrier of entry
- Autofluorescence and stained tissue stability a potential issue

Imaging Mass Cytometry™





Easy workflow that fits well with needs of clinical applications

- 40+ unique markers at once
- 1 mm² ROI in one hour
- No artifacts from FFPE, autofluorescence or tissue instability
- Initial investment required but running cost similar
- Easy labeling of antibodies

Visualize the Tissue Microenvironment

Gain unprecedented insights from highly multiplexed single-cell spatial biology

WORKFLOW



Subcellular resolution

Allows accurate and quantifiable phenotyping and cell function assessment

No autofluorescence

Reliable results when working with highly autofluorescent tissues (lung, gut, brain, skin)

High-plex, single staining

High-plex protein detection from formalin-fixed, paraffin-embedded (FFPE) or frozen tissue sections

Rapid panel design


Straight forward customization of markers with no worry about spill over and interactions

Proven


Hundreds of hands-on users and more than 130 peer-review published references

IMC Publications and National Clinical Trials

Imaging Mass Cytometry peer reviewed publications



Growing adoption of Mass Cytometry technology in clinical trials (CyTOF and IMC)




Insights into Cancer Therapy Resistance Using IMC

Key Cancer Insight


Analysis of IMC images identify **CD163-Arg1^{hi} macrophages** as a potential therapeutic target in hepatocellular carcinomas

Single cell analysis shows the **significance of cellular communities** in assessing immuno-therapy response

Data is pivotal for **quantitative models that predict clinical trial outcomes**



CD3
CD8
CD45
PanK
CD163
 α SMA
CD4





CD68
Foxp3
CD45
PanK
CD15
CD16
CD20

IMC images from a 27-marker panel

responders



non-responders



tSNE and pie charts showing heterogeneity in treatment responders and non-responders

Popel Lab
Sidney Kimmel Comprehensive Cancer Center,
Johns Hopkins University School of Medicine


Mi, H. et al. *Frontiers in Immunology* (2022)

Acute Lung Injury Insights Using IMC


Key COVID-19 Insights

Biologically interpretable landscape of lung pathology from a structural, immunological and clinical standpoint using a 38-marker panel

Provides evidence that SARS-CoV-2 induces a localized hyperinflammatory state associated with lung damage and identifies unique features particular to late COVID-19



Experimental design of IMC panel used with healthy and COVID-19 lung tissue samples



Microanatomy and immune content of the disease groups


Elemento and Schwartz Labs, Weill Cornell Medicine
Rendeiro, A.F. et. al. *Nature* (2021)

Concurrent Protein and Transcript Imaging

Key Cancer Insights


Concurrent imaging of **protein markers and RNA transcripts** enables a pivotal view of **chemokine landscape and immune infiltration** in metastatic melanoma samples

Imaging of melanoma **tumor microenvironment** provides novel insights into cellular recruitment and **anti-tumor activity**



Concurrent protein and RNA transcript imaging workflow

Bodenmiller Lab, University of Zurich
Hoch T. et al. *Science Immunology* (2022)




Protein and RNA transcript images

Patient Stratification in Breast Cancer


Key Cancer Insight

Using a 35-marker IMC panel, 352 breast cancer patients were characterized to reveal **18 new subtype groups**

Expands histological stratification as an indicator of immunotherapy response or patient survival



IMC images of breast cancer tissue



Enhanced stratification of 18 new subgroups using IMC

Bodenmiller Lab, University of Zurich
Jackson et al. Nature (2020)

Visualize Spatial Biology. Confidently.

Unprecedented visualization of complex cellular phenotypes and their relationships to reach insights quickly

- No autofluorescence to interfere with results
- Accurate and quantifiable

The **trusted** high-plex imaging system for discovery and translational researchers

- Proven in over 200 publications
- Fastest sample to insight for high-plex imaging

Mass Cytometry has long **runway** ahead in terms of number of markers, speed, resolution and cost and we are **investing**

Bridging discovery to clinical trials.

Hyperion+
Imaging System





Unleashing tools to
accelerate breakthroughs
in human healthTM